CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionReturn on equity is -210.3%, lower than 95% of its Biotechnology peers (median -22.3%)
- FinancialsAltman Z-Score -0.67: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
404.25MUSDvs all stocks (USD)
Revenue (TTM)
116.93MUSDvs all stocks (USD)
Profit Margin
-184.24%vs Biotechnology peers
Beta
0.9980xvs all stocks
52-Week Change
-58.18%vs all stocks
Market Capitalization
404.25MUSDvs all stocks (USD)
Enterprise Value
433.50MUSDvs all stocks (USD)
Forward P/E
-4.55xvs Biotechnology peers
Price to Sales (TTM)
3.47xvs Biotechnology peers
Price to Book (MRQ)
32.38xvs Biotechnology peers
Enterprise to Revenue
3.71xvs Biotechnology peers
Enterprise to EBITDA
-2.02xvs Biotechnology peers
Gross Margin
61.83%vs Biotechnology peers
Profit Margin
-184.24%vs Biotechnology peers
Operating Margin
-182.62%vs Biotechnology peers
Return on Assets (TTM)
-48.02%vs Biotechnology peers
Return on Equity (TTM)
-210.35%vs Biotechnology peers
Revenue (TTM)
116.93MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.18USDUpdated Sep 28, 2026Quarterly Revenue Growth
114.20%vs Biotechnology peers
Gross Profit (TTM)
68.22MUSDvs all stocks (USD)
EBITDA (TTM)
-214.65MUSDvs all stocks (USD)
Net Income (TTM)
-215.43MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
114.15%vs Biotechnology peers
Operating Cash Flow (TTM)
-196.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-117.70MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
84.28MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
20.42MUSDFY2025 · Dec 31, 2025Gross Profit
63.85MUSDFY2025 · Dec 31, 2025Operating Income
-179.45MUSDvs all stocks (USD)
Pre-tax Income
-171.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
-80.00KUSDFY2025 · Dec 31, 2025Net Income
-171.30MUSDFY2025 · Dec 31, 2025EBIT
-168.78MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-168.78MUSDFY2025 · Dec 31, 2025Research & Development
13.18MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
230.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.67MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.60MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.74USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.74USDFY2025 · Dec 31, 2025Basic Shares Outstanding
98.57MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
98.57MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-171.30MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-192.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-192.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
41.32MUSDFY2025 · Dec 31, 2025Interest Paid
2.45MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-171.30MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
-4.16MUSDFY2025 · Dec 31, 2025Stock-based Compensation
22.09MUSDFY2025 · Dec 31, 2025Other Non-cash Items
337.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-17.20MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.34MUSDFY2025 · Dec 31, 2025Capital Expenditures
-339.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-242.03MUSDFY2025 · Dec 31, 2025Sale of Investments
307.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-7.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
56.77MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
96.26MUSDFY2025 · Dec 31, 2025Other Financing Charges
2.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
98.92MUSDFY2025 · Dec 31, 2025Shares Outstanding
99.44MSharesUpdated Sep 28, 2026Float Shares
48.03MSharesUpdated Sep 28, 2026Shares Short
23.07MSharesUpdated Sep 28, 2026Short Ratio
14.55daysvs all stocks
Short % of Shares Outstanding
33.45%vs all stocks
% Held by Insiders
16.18%vs all stocks
% Held by Institutions
92.08%vs all stocks
Total Cash (MRQ)
143.84MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.45USDUpdated Sep 28, 2026Total Debt (MRQ)
171.60MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
13.72xvs Biotechnology peers
Current Ratio (MRQ)
3.48xvs Biotechnology peers
Book Value per Share (MRQ)
0.1260USDUpdated Sep 28, 2026Total Assets
327.65MUSDvs all stocks (USD)
Total Current Assets
284.90MUSDFY2025 · Dec 31, 2025Total Liabilities
213.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
42.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
174.25MUSDFY2025 · Dec 31, 2025Total Current Liabilities
39.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
41.32MUSDFY2025 · Dec 31, 2025Other Short-term Investments
203.67MUSDFY2025 · Dec 31, 2025Accounts Receivable
25.35MUSDFY2025 · Dec 31, 2025Inventory
8.37MUSDFY2025 · Dec 31, 2025Accounts Payable
5.72MUSDFY2025 · Dec 31, 2025Deferred Revenue
609.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
588.00KUSDFY2025 · Dec 31, 2025Long-term Debt
96.37MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
72.14MUSDFY2025 · Dec 31, 2025Common Stock (Book)
10.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-294.60MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
114.26MUSDvs all stocks (USD)
52-Week Low
4.02USDUpdated Sep 28, 202652-Week High
13.15USDUpdated Sep 28, 202652-Week Change
-58.18%vs all stocks
Beta
0.9980xvs all stocks
50-Day MA
5.48USDUpdated Sep 28, 2026200-Day MA
8.26USDUpdated Sep 28, 2026Avg 10-Day Volume
1.61MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.65MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.18USDUpdated Sep 28, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -210.3%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -2.10Industry median: -0.22Industry P5: -1.57Peers compared: 260
Debt-to-equity is 13.72×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 13.72Industry median: 0.07Industry P95: 0.93Peers compared: 260
Price-to-book is 32.38×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 32.38Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: -1.84
Significant cash reserves alongside high leverageNotable
Cash (USD): 143,844,992Total Debt (USD): 171,603,008Debt-to-Equity: 13.72
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.48Altman Z-Score: -0.67
Financial Health
Altman Z-Score -0.67: distress zoneCritical
Altman Z-Score: -0.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Abivax SA
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ADC Therapeutics S.A.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Ifishdeco Tbk PT
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated